Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone Clear all
Recruiting Phase 3 Interventional

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

NCT05561387
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
397
States / cities
Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 287 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 17, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional Results available

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

NCT03121534
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer, Richter's Transformation
Interventions
Blinatumomab, Dexamethasone, Ibrutinib, Nivolumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 17, 2026, 3:52 PM EDT
Terminated Phase 4 Interventional Results available

Calcific Tendonitis Treatment: Barbotage vs. Barbotage With Cortisone Injection

NCT04126278
View directory record Official record
Conditions
Calcific Tendinitis
Interventions
Barbotage, Dexamethasone
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

NCT04465864
View directory record Official record
Conditions
Glaucoma, Primary Open Angle, Cataract
Interventions
Intracanalicular Dexamethasone, 0.4 mg insert
Drug
Lead sponsor
Wolstan and Goldberg Eye Associates
Network
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans

NCT02891798
View directory record Official record
Conditions
Pain
Interventions
Bupivacaine + CBD (clonidine, buprenorphine, dexamethasone), Bupivacaine Only (control arm)
Drug
Lead sponsor
Brian Williams
Federal
Eligibility
18 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

NCT00507416
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Melphalan, Prednisone, Thalidomide
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
234
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Sedona, Arizona + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 1 Interventional Results available

Study of Proton Therapy in Adjuvant Pancreatic Cancer

NCT03885284
View directory record Official record
Conditions
Resected Pancreatic Adenocarcinoma
Interventions
mFOLFIRINOX, Proton beam radiation
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 17, 2026, 3:52 PM EDT
Terminated Phase 3 Interventional

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

NCT01002248
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Perifosine, Perifosine Placebo, Bortezomib, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
39
States / cities
La Verne, California • San Francisco, California • San Pablo, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Sep 17, 2026, 3:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Dexamethasone for Ureteral STent Symptoms (DUSTS)

NCT06930690
View directory record Official record
Conditions
Ureteral Stent-Related Symptom
Interventions
Dexamethasone Sodium Phosphate Injection 20 mg, Dexamethasone Sodium Phosphate Injection 4mg
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT01212952
View directory record Official record
Conditions
Refractory Multiple Myeloma
Interventions
pomalidomide, bortezomib, dexamethasone, laboratory biomarker analysis, gene expression analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Sep 17, 2026, 3:52 PM EDT
Terminated Phase 2 Interventional Results available

Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

NCT01312818
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Vorinostat, Dexamethasone, Methotrexate, Imatinib mesylate
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
2 Years to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

NCT03275285
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
isatuximab SAR650984, carfilzomib, dexamethasone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
San Francisco, California • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Not applicable Interventional Results available

Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

NCT01490060
View directory record Official record
Conditions
Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
Interventions
Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 2 Interventional

Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally

NCT00083538
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Thalidomide, Cisplatinum, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2010 · Synced Sep 17, 2026, 3:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide

NCT05434689
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide, Daratumumab, Dexamethasone, Carfilzomib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Birmingham, Alabama • Columbus, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 17, 2026, 3:52 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

NCT07224672
View directory record Official record
Conditions
Amyloidosis
Interventions
Belantamab mafodotin, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 17, 2026, 3:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945
View directory record Official record
Conditions
Multiple Myeloma
Interventions
AZD0305, Elranatamab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT02963493
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan flufenamide (Melflufen), Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
9
States / cities
Whittier, California • Gainesville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 17, 2026, 3:52 PM EDT
Not listed Not applicable Interventional

Nerve Block for Pain Control After Fracture Surgery

NCT05391464
View directory record Official record
Conditions
Ankle Fractures, Distal Radius Fracture
Interventions
Peripheral Nerve Block
Procedure
Lead sponsor
MaineGeneral Health
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Augusta, Maine
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"

NCT03081416
View directory record Official record
Conditions
Headache, Intranasal Ketamine
Interventions
Ketamine, Normal saline, Metoclopramide, Ketorolac, Dexamethasone, Benadryl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 2 Interventional Results available

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

NCT01626664
View directory record Official record
Conditions
Adult T-cell Leukemia-Lymphoma
Interventions
KW-0761, Pralatrexate, gemcitabine plus oxaliplatin, DHAP
Biological · Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

NCT01311687
View directory record Official record
Conditions
Multiple Myeloma
Interventions
pomalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 17, 2026, 3:52 PM EDT
Completed Phase 4 Interventional

DEXTENZA Therapy for Treatment of Allergic Conjunctivitis

NCT04708821
View directory record Official record
Conditions
Bilateral Conjunctivitis (Disorder)
Interventions
Dexamethasone ophthalmic insert 0.4Mg, 0.2% loteprednol etabonate ophthalmic suspension, olopatadine hydrochloride ophthalmic solution 0.7%
Drug
Lead sponsor
Clinical Research Center of Florida
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Pompano Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Sep 17, 2026, 3:52 PM EDT
Active, not recruiting Phase 2 Interventional

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 17, 2026, 3:52 PM EDT